04.01.2023 15:00:00
|
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
SAN FRANCISCO, Jan. 4, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until February 11, 2023.
About Nektar
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology and immunology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama. Further information about the company and its drug development programs and capabilities may be found online at https://www.nektar.com.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-301713076.html
SOURCE Nektar Therapeutics
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nektar Therapeuticsmehr Nachrichten
17.01.25 |
NASDAQ Composite Index-Titel Nektar Therapeutics-Aktie: So viel Verlust hätte ein Nektar Therapeutics-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
14.01.25 |
Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels schwächer (finanzen.at) | |
14.01.25 |
Freundlicher Handel in New York: NASDAQ Composite präsentiert sich fester (finanzen.at) | |
14.01.25 |
Schwache Performance in New York: So bewegt sich der NASDAQ Composite am Dienstagmittag (finanzen.at) | |
10.01.25 |
Zurückhaltung in New York: NASDAQ Composite verliert schlussendlich (finanzen.at) | |
10.01.25 |
Zurückhaltung in New York: NASDAQ Composite am Freitagmittag in der Verlustzone (finanzen.at) | |
10.01.25 |
NASDAQ Composite Index-Titel Nektar Therapeutics-Aktie: So viel Verlust hätte ein Investment in Nektar Therapeutics von vor 3 Jahren bedeutet (finanzen.at) | |
10.01.25 |
Börse New York: NASDAQ Composite zeigt sich zum Start des Freitagshandels schwächer (finanzen.at) |
Analysen zu Nektar Therapeuticsmehr Analysen
Aktien in diesem Artikel
Nektar Therapeutics | 0,88 | 1,45% |